Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.53 USD | -2.06% |
|
+3.90% | -25.37% |
Business Summary
Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.
Number of employees: 382
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Recombinant Human C1 Esterase Inhibitor
100.0
%
| 196 | 100.0 % | 227 | 100.0 % | +15.98% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
97.5
%
| 190 | 97.3 % | 221 | 97.5 % | +16.17% |
Europe and Rest of World
2.5
%
| - | - | 6 | 2.5 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sijmen de Vries
CEO | Chief Executive Officer | 65 | 08-10-12 |
Jeroen Wakkerman
DFI | Director of Finance/CFO | 55 | 20-11-15 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 52 | - |
Mireille Sanders
COO | Chief Operating Officer | 56 | 19-04-30 |
Compliance Officer | 60 | 20-03-31 | |
Michael Levitan
IRC | Investor Relations Contact | 66 | - |
Stephen Toor
PRN | Corporate Officer/Principal | 52 | 20-12-14 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Pykett
BRD | Director/Board Member | 60 | 20-12-10 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 21-05-18 |
Sijmen de Vries
CEO | Chief Executive Officer | 65 | 08-10-12 |
Steven Baert
BRD | Director/Board Member | 50 | 21-03-31 |
Deborah Jorn
BRD | Director/Board Member | 66 | 19-05-21 |
Barbara Yanni
BRD | Director/Board Member | 69 | 20-12-10 |
Director/Board Member | 58 | 21-05-18 | |
Richard Peters
CHM | Chairman | 61 | 23-09-24 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 673,441,363 | 662,544,910 ( 98.38 %) | 0 | 98.38 % |
Company contact information
![address Pharming Group N.V.(PHAR)](https://cdn.zonebourse.com/static/address/116960810.png)
Sector
Sales per region
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.53% | 848B | |
+35.80% | 627B | |
-3.66% | 363B | |
+15.06% | 318B | |
+9.18% | 299B | |
+5.89% | 234B | |
+15.98% | 225B | |
+15.67% | 179B | |
+2.47% | 167B |
- Stock Market
- Equities
- PHARM Stock
- PHAR Stock
- Company Pharming Group N.V.